Event-Driven Stocks

ZOGENIX, INC.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 2 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY21FY20FY19FY18FY17FY16
Revenue$74.7M$9.6M$3.6M$0$9.8M$28.9M
Operating income−$224.1M−$247.7M−$429.8M−$141.2M−$119.9M−$72.7M
Net income−$227.4M−$209.4M−$419.5M−$123.9M−$126.8M−$69.7M
Total assets$468.5M$651.1M$414.3M$648.3M$417.6M$231.5M
Total liabilities$289.5M$281.5M$169.2M$125.5M——
Equity$179.0M$369.7M$245.1M$522.8M$301.5M$120.8M
EPS (diluted)$-4.07$-3.90$-9.74—$-4.65$-2.81
Shares out.55.7M45.4M42.2M34.8M24.8M24.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2021
Operating margin
−299.8%
Net margin
−304.3%
Return on equity
−127.1%
Return on assets
−48.5%
Return on capital (ROCE)
−60.4%
Liabilities / assets
61.8%
Debt / equity
1.62×
Book value / share
$3.21
Revenue growth (YoY)
679.6%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2021
Altman Z″ (distress)
-9.77distress
Accruals / assets
−9.0%clean
Beneish M-Score
2.61elevated
Piotroski F-Score
3/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Beneish M-Score elevated — earnings-manipulation screen flag
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.